Potential impact of AUSFTA on Australia’s blood supply

Albert Farrugia
Med J Aust 2007; 186 (12): . || doi: 10.5694/j.1326-5377.2007.tb01091.x
Published online: 18 June 2007

To the Editor: In reference to the letter by Kennedy et al, reporting two patients who tested positive to human T-lymphotropic virus I/II (HTLV-I/HTLV-II) antibodies after administration of the intravenous immunoglobulin, Octagam (Octapharma Australia, Sydney, NSW),1 the Therapeutic Goods Administration (TGA) would submit that:

  • Albert Farrugia

  • Office of Devices, Blood and Tissues, Therapeutic Goods Administration, Canberra, ACT.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.